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Abstract: The dopamine transporter (DAT) plays a role in the termination of dopaminergic neurotransmission; thereby it is accepted as
the primary target of various psychostimulants. N-terminal phosphorylation of DAT has been proposed as a regulator in different DAT
functions, such as amphetamine-induced efflux or PKC/PKA-mediated responses. To understand the role of N-terminal conformational
changes in dopamine transporter structure and function, the fluorescence resonance energy transfer (FRET) method was applied to
various DAT constructs fluorescently labeled at the N-terminus and substrate-induced conformational changes were determined using
rhodamine-labeled cocaine analog JHC1-64 in three DAT mutants. The results indicated that the construct with YFP inserted into the
N-terminal position-55 displayed effective interaction with the substrate and simultaneous mutation of two serine residues (S7 and S12)
to alanine or aspartic acid demonstrated similar phenotypes as their wild-type (WT) counterparts. FRET was detectable for N-terminal
p55 YFP WT, Ser/Ala, and Ser/Asp forms, but there was no significant difference among the three mutants, contrary to our expectations
based on the previously proposed roles of these serine residues. In addition, three mutants (K264A, D345A, and Y335A) implemented
in the position-55 YFP background were also investigated and the importance of Y335 in the translocation cycle and in the process of
substrate release was verified.
Key words: Dopamine transporter, fluorescence resonance energy transfer, structure, phosphorylation, N-terminus of DAT

1. Introduction
Dopaminergic signaling has an indispensable role in
neurological disorders such as schizophrenia, bipolar
disorder, and attention deficit disorder. Duration of
dopaminergic signaling, and therefore its regulation,
is tightly coupled to the dopamine transporter (DAT),
which mediates rapid uptake of dopamine (DA) from the
synaptic cleft (Amara and Kuhar, 1993).
The transporter belongs to the family of
neurotransmitter transporters also known as sodium
symporters (NSSs). These proteins form a large family
encompassing other neurotransmitter transporters for
norepinephrine, serotonin, glycine, and GABA. All these
transporters have the common property of utilizing the
energy of the Na+ gradient to carry the substrate uphill
(Rudnick, 1997). In addition to dopamine transport, DAT
can also bind several psychostimulant drugs, including
amphetamine (AMPH) and cocaine. Indeed, DAT may be
the primary target for the rewarding properties of these
widely abused psychostimulants.
The N-terminus of transporters has indispensable
roles in monoamine transporters’ functions. The
N-terminus is the primary target of various kinases such
* Correspondence: oyaorun@yahoo.com
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as protein kinase A (PKA), protein kinase C (PKC),
and Ca2+/calmodulin-dependent kinase (CaM kinase
II); however, the role of phosphorylation by these
kinases is speculative. The first N-terminal 22 amino
acids have previously been shown to be phosphorylated
by PKC (Granas et al., 2003). When these 22 amino
acids were removed from the N-terminal, DAT (del
22 DAT) phosphorylation was abolished without
affecting PKC-induced internalization. In HEK-293
cells stably expressing del-22 DAT, AMPH-induced
DA efflux, but not DA uptake, was substantially
reduced. Phosphorylation of two serine residues at the
N-terminus, Ser 7 and Ser 12, was mainly found to be
essential for this response (Khoshbouei et al., 2004;
Kahlig et al., 2005). Mutation of serine 7, a site for PKCmediated phosphorylation, strongly reduced cocaine
analog affinity and also changed the zinc modulation of
cocaine analog 2β-carbomethoxy-3β(4-fluorophenyl)
tropane (CFT) binding, with opposite results in Ala and
Asp mutations (Moritz et al., 2013). Other protein kinases
also seem to affect nearby serine/threonine residues and
phosphorylation of these presumably acts as a modulator
of conformational equilibria and inhibitor binding.
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To address the role of the N-terminus and its
phosphorylation upon substrate or inhibitor binding, a
technique to characterize conformational changes of the
N-terminal tail of DAT expressed in HEK-293 cells was
established. By applying fluorescence resonance energy
transfer (FRET) between donor fluorophore yellow
fluorescent protein (YFP) fused into the N-terminal tail
and a rhodamine-labeled cocaine analog bound in the
transmembrane domain of DAT, the movement of the tail
relative to the fixed rhodamine position was monitored.
Evaluation of FRET signals revealed close encounters
between the residues upstream from position 55 and
the substrate binding site. DA uptake and binding of
2β-carbomethoxy-3β-(4-iodophenyl) tropane (RTI-55)
were unaffected upon phosphorylation.
N-terminal changes invoked by inhibitor binding
were further investigated in mutants that have been
shown to have roles in Zn2+-induced activity changes.
Zn2+ binds to a high-affinity Zn2+ binding site in DAT,
shaped by three coordinating residues: His 193, His 375,
and Glu 396. The effect of Zn2+, which was shown to be
a potent noncompetitive inhibitor of dopamine uptake,
was modulated by different mutations. The transporters
carrying one of the three mutations, K264A, Y335A, or
D345A , were all characterized by their decreased Vmax
and Km values for [3H] dopamine uptake and the addition
of Zn2+ into the medium resulted in a dose-dependent
increase in substrate intake (Loland et al., 2004).
Physiologic concentrations of Zn2+ also affected inhibitor
binding and AMPH-induced efflux in DAT (Scholze et
al., 2002; Meinild et al., 2004). In the present study, new
DAT forms with a YFP tag were constructed, and it was
determined that the insertion of a large YFP tag into p55
of DAT did not affect any Zn2+-induced properties of
Zn2+-sensitive mutants. Later, structural properties were
investigated by FRET analyses and confirmed previously
suggested roles of these mutants to alter the distribution
between different equilibrium states of DAT transport.
In particular, Tyr-335 mutation clearly disrupted energy
transfer, providing further evidence for the role of Tyr-335
in an intramolecular “gating network” and conformational
equilibrium of the protein.
2. Materials and methods
2.1. Cloning
A synthetic hDAT gene with artificially introduced
restriction enzyme sites (SynDAT) was used as a template
in site-directed mutagenesis studies (Loland et al., 2004).
This gene was inserted into the bicistronic mammalian
expression vector pCIHygro and the protein was shown
to have identical expression and function to hDAT (Rees
et al., 1996; Saunders et al., 2000, Hastrup et al., 2001).
The constructs containing YFP were synthesized by two-

step PCR using Phusion polymerase (Finnzymes, Espoo,
Finland) and SynDAT as a template. All constructs
were confirmed by restriction enzyme digestion and
by automated DNA sequence analysis (MWG Biotech,
Ebersberg, Germany). All restriction enzymes were from
New England Biolabs (Beverly, MA, USA).
2.2. Cell culture and transfections
Cell culture and transfection were maintained as
described previously (Orun et al., 2009). For stable cell
lines, the transfected pool was selected using 350 µg/mL
hygromycin (Invitrogen, Carlsbad, CA, USA). Stable cell
lines containing K264A, D345A, and Y335A mutations
were maintained with a supplement of 10 µM Zn2+ in the
culture.
2.3. Uptake experiments
Uptake assays were performed using 2,5,6-[3H]-dopamine
(7-21 Ci/mmol) (Amersham Biosciences, Little Chalfont,
UK). Cells were seeded at a density of 1 × 105 cells/well
in 24-well plates coated with 20 mg/mL poly-D-lysine
(Sigma, St. Louis, MO, USA) in PBS buffer 2 days before
the assay. The uptake buffer contained 10 µM catecholo-methyltransferase inhibitor Ro 41-0960 to prevent
dopamine degradation. Unlabeled dopamine ligands
(Research Biochemicals, Billingham, UK) were added
in concentrations of 10 nM to 1 mM. After addition of
radioactive dopamine (90 nM [3H] dopamine), the uptake
reaction was performed in 5 min at 37 °C. All samples were
analyzed in triplicate. Statistically analyzed assays are the
result of at least three independent experiments, since this
was found to be sufficient for ligand binding and activity
tests (Loland et al., 2002). The samples were counted in a
Wallac Tri-Lux β-scintillation counter (NEN). Data were
analyzed by nonlinear regression analysis using Graph
Prism v5.01 fitting and plotting software (GraphPad, San
Diego, CA, USA).
2.4. Donor bleach FRET
Cells were seeded in 8-well Lab-Tek chambers at 4 × 104
cells/well 2 days before the experiment. The donor bleach
method was applied, in which protection of YFP from
bleaching (488 nm, 60% laser power) was an indicator of
FRET between the donor YFP and the acceptor rhodaminelabeled cocaine analog (JHC1-64). A wavelength of 488
nm at 10% power was used as excitatory light, while the
emission spectrum was confined using a BP 505-530 filter.
A 4× zoom was applied during all measurements. RTI-55
was used as a control nonfluorescent cocaine analog. Cells
were bleached in the YFP channel by scanning a region
of interest (ROI) 60 times using the 514 argon laser line.
The number of repeats was 8–12 for each experiment, with
various ROI selections from different cells. Bleaching time
constants (tbl) of donor-only (td) or donor- and acceptor
(td,a)-labeled cells were calculated for each image and
energy transfer efficiencies were calculated using E(%) =
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100 × [1 – (td / td,a)] (Damjanovich et al., 1995). Distances
were determined using efficiency values according to the
following formula: r = R0 {(1 / E – 1)}1/6.

Arg60 and Asp436 was shown to drive DAT to an outwardfacing substrate binding conformation (Kniazeff et al.,
2008; Guptaroy et al., 2009). Therefore, YFP, a 27-kDa tag,
was introduced into position 55, a few residues preceding
these crucial amino acids, and surface expression of the
construct was examined. Surface localization of this
construct, together with other mutants built in this study,
was found to be comparable to wild-type (WT) human
SynDAT (Figures 2A–2C).
Following the construction of N-term p55 YFP,
double-Ser mutants (mutated either to aspartic acid
[Ser7Asp and Ser12Asp] to mimic the phosphorylated
state of the transporter or to alanine to eliminate
phosphorylation [Ser7Ala and Ser12Ala] on the N-term
p55 YFP background) were established, and dopamine
uptake capabilities were determined for all constructs
(Figure 3A).The EC50 values for all constructs were similar,
as summarized in Table 1. The values are from means of
three independent experiments performed in triplicate.
Affinities for cocaine analog RTI-55 were also
determined for all groups. Competition binding

3. Results
3.1. Characterization of phospho-mimicking mutants in
the p55 YFP background
YFP was introduced into position 55 and phosphomimicking mutants serine-to-alanine (Ser7/12Ala) or
serine-to-aspartic acid (Ser7/12Asp) were constructed as
shown in Figure 1. Transient or stable cell lines transfected
with constructs were then tested for their dopamine uptake
ability, surface expression, and FRET.
Previous studies reported that truncation of the first
58 amino acids of DAT (del 58 DAT) changed neither
localization nor surface expression and uptake, but
truncation of the first 65 amino acids abolished dopamine
transport, indicating a crucial role for residues between 59
and 65 (Gu et al., 2001; Sorkina et al., 2003). In addition,
mutation of Thr 62 showed a clear influence on the influx–
efflux balance of the transporter, and a salt bridge between
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Figure 1. Topologic representation of human SynDAT with introduced mutations. Ser/Ala (Ser7/12 Ala) and Ser/Asp (Ser7/12 Asp)
mutations (pink/red dots) together with K264A, D345A, and Y335A mutations on the N-term p55 YFP background depicted in the
same picture.
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Figure 2. Representative picture for surface expression of constructs: (A) WT, (B) Ser/Asp (S7D and S12D) mutant, and (C) Y335A
mutant forms of N-term p55 YFP human SynDAT. Cells were seeded into 8-well Lab-Tek II glass chamber slides (Nalge, Penfield, NY,
USA) 24 h before analysis and visualized using a Zeiss (Oberkochen, Germany) LSM 510 confocal laser scanning microscope with an
oil immersion 63× water objective. A 150-mW Ar-Kr laser was used for the excitation of YFP at 488 nm, and the emitted light passed
through a 505-nm long-pass filter.
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Figure 3. [3H] dopamine uptake of N-term p55 YFP-labeled DAT mutants. YFP was placed at position 55 of the dopamine
transporter by two-step PCR-based mutagenesis in the background of the SynDAT template, as described in the text. The effect
of phosphorylations at two serine positions (Ser7 and Ser12), together with zinc-activating mutations, was examined. (A)
Uptake curves of N-term p55 YFP-labeled WT human SynDAT, Ser/Ala, and Ser/Asp mutants with increasing concentrations
of dopamine. (B) Uptake curves of N-term p55 YFP-labeled WT human SynDAT and K264A, D345A, and Y335A mutants with
increasing concentrations of dopamine. (C) Uptake curves of N-term p55 YFP-labeled WT human SynDAT and K264A, D345A,
and Y335A mutants with zinc addition. All experiments were performed at least in triplicate.
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Table 1. [3H] dopamine uptake and binding characteristics of human SynDAT and its YFP-labeled mutants.
EC50 (µM)

Vmax

Km (µM)

[SE interval]

(fmol/min/10 cells ± SE)

[SE interval]

SynDAT

1.45 [1.01–2.08]

20,673 ± 2676

1.45 [1.01–2.08]

NTp55YFPSynDAT

0.92 [0.76–1.11]

17,327 ± 4269

1.15 [0.94–1.41]

NTp55YFPSynDAT
StoA

1.0 [0.88–1.15]

14,482 ± 1212

0.95 [0.83–1.08]

NTp55YFPSynDAT
StoD

1.13 [1.12–1.14]

17,074 ± 1827

1.06 [1.04–1.08]

5

The values were calculated from nonlinear regression analysis of uptake data using GraphPad Prism v5.0. All values
were calculated from the means of at least three repetitions.

experiments were performed on HEK-293 cells expressing
the appropriate constructs and IC50 values for cocaine
analog RTI-55 were 5.85 nM (4.45–7.7) for WT human
SynDAT, 2.52 nM (1.65–3.85) for N-term p55 YFP
SynDAT, 3.07 nM (1.67–5.67) for N-term p55 YFP
SynDAT/S-to-A, and 3.43 nM (2.42–4.86) for N-term p55
YFP SynDAT/S-to-D constructs.
3.2. Characterization of mutant Zn2+-responsive residues
in the p55 YFP background
All three Zn2+-responsive constructs built in this study,
namely N-term p55 YFP D345A, N-term p55 YFP K264A,
and N-term p55 YFP Y335A, displayed reduced Vmax and
Km values compared to the WT in dopamine uptake assays
(Table 2). Vmax for N-term p55 YFP D345A and K264A was
nearly 10% of N-term p55 YFP WT human SynDAT, while
it further decreased to 6% in the N-term p55 YFP Y335A
construct (Figure 3B).

The effect of Zn2+ on uptake was also similar to the
previously reported behavior of WT hDAT and its Zn2+responsive mutants (Loland et al., 2003). Zn2+ showed
biphasic inhibition of N-term p55 YFP-tagged human
SynDAT (data not shown) and that inhibition was
converted to stimulation in the aforementioned N-term
p55 YFP-tagged mutants in a dose-dependent manner
(Figure 3C).
These results confirmed that placing a YFP tag into
position 55 did not cause a significant change in the
functionality of the WT or mutant forms of the transporter,
neither in dopamine uptake nor in the potentiating effect
of Zn2+.
3.3. FRET analyses
FRET was examined between a rhodamine-labeled
cocaine analog (JHC1-64) and N-term p55 YFP human
SynDAT mutants. The ligand was found in FRET distance

Table 2. [3H] dopamine uptake and binding characteristics of human SynDAT and its Zn2+-sensitive mutants.
EC50(µM)
[SE interval]

Vmax
(fmol/min/105 cells ± SE)

Km (µM)
[SE interval]

IC50 (µM)
(Zn2+)

Ki
(RTI-55)

NTp55YFP
SynDAT

0.92
[0.76–1.11]

13,842 ± 3413

1.15
[0.94–1.41]

0.47

5.5
[4.9–6.2]

NTp55YFP
SynDATK264A

1.37
[1.36–1.38]

1697 ± 132

0.68
[0.66–0.69]

1.98

16.3
[13.4–2.00]

NTp55YFP
SynDATD345A

0.8
[0.7–0.8]

1591 ± 545

0.95
[0.47–1.9]

2.06

5.5
[4.9–6.2]

NTp55YFP
SynDATY335A

0.14
[0.13–0.14]

895 ± 59

0.29
[0.18–0.48]

3.9

300
[217–439]

The values were calculated from nonlinear regression analysis of uptake data using GraphPad Prism v5.0. Zn2+ inhibition of [3H]
dopamine uptake was fitted to either a two-site or a one-site model. The binding of RTI-55, a nonfluorescent cocaine analog control used
in FRET measurements, was also tested in mutant constructs. All values were calculated from the means of at least three repetitions.
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with the YFP label in N-term p55 YFP human SynDAT,
and there was no detectable change in FRET when S/D or
S/A mutations were introduced (Figures 4A and 4B).
FRET was also applied to mutants that have Zn2+induced effects on both substrate- and inhibitor-binding
properties of WT DAT (Figures 5A–5C). Prolongation of
half-life was observed in N-term p55 YFP K264A, but the
FRET signal was weak with a calculated proximity of 63 Å
between position 55 and the bound cocaine analog, the same
as for the S/D form. In the D345A mutation, fluorescent
pairs were still in FRET distance, but the proximity was
lower (Table 3). There was no detectable energy transfer
in the Y335A form. Affinity of the Y335A construct for
cocaine analog RTI-55 was also very low. These findings
are pertinent to the dramatic changes observed in Y335A

Donor (YFP) emission (Percent of maximal)

4. Discussion
DAT is the major target for psychostimulants like cocaine
and amphetamine. The last decade provided important
insights into to the structure–function relationship of
this large integral protein. Crystallization of a bacterial
homolog, leucine transporter (LeuT), and more recently,
X-ray models of DAT from Drosophila (dDAT) showed
that the 3D structure of transporters have high folding
similarities, despite their low sequence identity across
species (22% for LeuT and 50% for dDAT with the
eukaryotic NSS family) (Yamashita et al., 2005; Forrest et
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mutants, verify N-term R60–Y335 bond formation, and
show that N-term YFP-tagged DAT can be a useful tool to
study intramolecular conformational regulation.
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Figure 4. FRET in N-term p55 YFP-labeled (A) S-to-D and (B) S-to-A mutants. Cocaine analog JHC1-64induced changes in FRET in N-term p55 YFP-labeled S-to-D and S-to-A mutants were reversed by the addition of
nonfluorescent cocaine analog RTI-55. Data are means of 8–12 independent experiments.
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respectively. Both uptake experiments and FRET studies indicated that position Y335 has a
critical role in function, and that mutation of this residue severely impairs conformational stability
distribution during substrate translocation. Data are means of 8–12 independent experiments.
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Table 3. FRET efficiencies and estimated intramolecular proximities between the
rhodamine-labeled cocaine analog and the YFP protein inserted into the N-terminus
of human SynDAT.
r (Å)

E (%)
NTp55YFPSynDAT

14

69.4

NTp55YFPSynDATStoA

31

58.6

NTp55YFPSynDATStoD

23

62.7

NTp55YFPSynDATK264A

20

62.9

NTp55YFPSynDATD345A

0.05

83.7

NTp55YFPSynDATY335A

-

-

Bleaching time constants (tbl) of donor-only (td) or donor- and acceptor (td,a)-labeled
cells were calculated using GraphPad one-phase exponential decay analysis. Energy
transfer efficiencies and distances were calculated as described in Section 2. R0 was
estimated as 51.29 Å for a YFP–rhodamine pair using available values for the quantum
yield and extinction coefficients of the donor–acceptor pair.

al., 2007; Indarte et al., 2007; Beuming et al., 2008; Shan
et al., 2011; Krishnamurthy and Gouaux, 2012; Penmatsa
et al., 2013). These studies, together with models built
upon the available data, indicated that the binding sites
for cocaine and cocaine analogs are deeply buried between
TM 1, 3, 6, and 8 and overlap with binding sites for
substrates such as dopamine and amphetamine (Beuming
et al., 2008).
Amphetamine is a dopamine reuptake inhibitor.
Besides its role as a blocker of DA uptake, the main effect
of amphetamine is through induction of DA efflux. This
process works by increasing the number of inwardfacing binding sites. Phosphorylation of serine residues
(Ser7 and Ser12) in the N-terminal tail of DAT regulates
amphetamine-induced DA efflux through an unknown
mechanism (Khoshbouei et al., 2004). To characterize
conformational changes upon phosphorylation of
N-terminus, FRET distances between the N-terminus
involving phospho-mimicking mutations and the cocainebinding site were assessed. Since the crystal structure
data of LeuT start from position 56 of wild-type DAT, a
YFP tag was placed into position 55. These results, in
accordance with the model based on the crystal structure
of LeuT, verify the role of residues upstream to position 55
in activation of DAT (Beuming et al., 2008). In an earlier
study, we reported that there is no FRET interaction
between the extreme N-terminus or its phosphomimicking mutants and the cocaine-analog binding site
(Orun and Tiber, 2015). The lack of FRET for the N-term
position 1, together with the current finding for position
55, suggests that the very end of DAT has an extended
structure, further away from ligand binding sites.

Since preliminary experiments designed to determine
binding and interaction domains of DAT relied on
manipulating an endogenous Zn2+ binding site, we also
wanted to explore possible large-scale conformational
changes in cocaine-analog binding in the presence of Zn2+.
Zn2+, in micromolar concentrations, has been shown to act
as a potent noncompetitive blocker of dopamine uptake
and to stabilize the outward-facing conformation of DAT.
Zn2+ also potentiates binding of cocaine-like blockers,
such as WIN 35,428. Identification of Zn2+ binding sites
His193, His375, and Glu396 pointed to a spatial proximity
between the EC2 loop and the top of the TM7 and TM8
domains. Recently, D206 was confirmed as the fourth
coordinating residue in zinc binding (Stockner et al.,
2013). The mutation of an intracellular tyrosine to alanine
(Y335A) converted the inhibitory Zn2+ switch into an
activating one. This tyrosine was placed in a conserved
trafficking motif (YXXF) and mutation of this residue
did not change the surface expression or internalization
pattern of the transporter. The Y335A mutant had greatly
reduced dopamine reuptake compared to other constructs,
and uptake velocity was less than 1% of that of the wild
type. Vmax, however, was found to be partially restored
when Zn2+ was added in micromolar concentrations,
indicating that Tyr-335 may be critical in the partitioning
of conformational states in the translocation cycle of DAT
(Loland et al., 2002). Additionally, there was a 20-fold
increase in affinity for substrates, contrary to a 150-fold
decrease for inhibitors such as CFT or RTI-55 (Loland et
al., 2004). Substitution experiments showed that K264A,
D345A, and D436A mutants also produced a phenotype
similar to Y335A.
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To better understand the conformational changes
in DAT after binding to inhibitors, the efficiency of
fluorescence energy transfer in N-terminally labeled p55
YFP mutants containing one of the mutations Y335A,
D345A, or K264A was measured. Dopamine uptake
capacities of all mutants were tested and found to be
reduced in all constructs, as expected. In N-term p55 YFPtagged K264A human SynDAT, JHC1-64 was in FRET
distance with respect to position 55. The distance was
greater than 80 Å for N-terminus p55 YFP-tagged D345A
and was out of FRET range (>100 Å) for the N-terminus
p55 YFP-tagged Y335A mutant.
The relationship between the N-terminus and substrate
binding site is of critical importance in DAT function.
In recent years, two substrate binding sites, namely S1and S2-, were well clarified by modeling and molecular
dynamic studies as well as experimental data (Shan et al.,
2011; Cheng et al., 2015; Zomot et al., 2015). Molecular
details of the communication and allosteric interaction
between the two sites and the proposed mechanism in
substrate release seem to involve many residues and various
dynamics. According to these studies, DA release from the
S1 site involves a sequence of arrangements involving F69,
F76, F332, W63, and Y335. The role of the N-terminus as
a network defining an intracellular “gate” was also assessed
by a proposed salt bridge between R60 and D436, which is
stabilized by a cation–p interaction between R60 and Y335
(Kniazeff et al., 2008). Furthermore, Guptaroy et al. showed
that T62 mutation in the N-terminus results in dramatically
reduced [3H] dopamine uptake and this mutant prefers an
inward-facing conformation, similar to Y335A mutants
(Guptaroy et al., 2009). D345, on the other hand, was
characterized as an important element in both forward
and reverse transport of DA. Although uptake inhibition

by inhibitors did not seem to be seriously affected by D345
mutants, all D345 mutants had extremely low Vmax and Km
values for DA uptake (Chen et al., 2004). D345 possibly
has a role in inhibitor binding and mutation of that residue
converts DAT to a partially active state, which alters the
interaction of cocaine analogs with the transporter (Chen
et al., 2004). Although available data do not support direct
contact between D345 and Y335, both residues have been
suggested to be the active participants of a network of
intermolecular connections taking place during substrate
translocation. The present findings indicate that both
mutants result in the diminution of FRET between TM1a
and the substrate binding state upon cocaine binding,
though the effect on D345 is less dramatic.
Overall, the data presented here emphasize the role
of the interaction between parts of the N-terminus 55
amino acids further from the extreme end and other TM
regions, especially TM6b, in relation to S1-site occupation
and dopamine translocation. No major change in
conformation was detected between the phosphorylated
and nonphosphorylated forms of the N-terminus upon
cocaine analog binding. These findings support the
estimated movement of the N-terminus, specifically the
movement of region TM1a away from TM6b upon Y335A
mutation. They also show that Tyr 335 and Asp 345 are
active parts of the conformational rearrangement during
the transition from the DA-bound S1 state to the inwardfacing conformation, while the role of K264 may be more
subsidiary in comparison.
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